Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus BACTROBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus BACTROBAN.
ALTABAX vs BACTROBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic